Key points are not available for this paper at this time.
Abstract Ovarian cancer lacks effective therapy. Here, we reported three metastatic ovarian cancer patients administrated with a noval TIL therapy, which was designed glycosylphosphatidylinositol-anchored membrane-bound interleukin-7 (mbIL-7-GPI) to engineer TILs (mbIL-7-TIL) through piggyBac transposon system. In three advanced ovarian cancer patients, infusion of mbIL-7-TILs showed endurable toxicity and prolonged clinical response. After infusion, peripheral mbIL-7-TILs peaked around 5-7 days and then sharply decreased. We found that several clones of engineered T cell and subsequent clones of original T cells underwent significant proliferation in patient 1. Seven months post infusion, mbIL-7-TILs could be detected in tumor liquefactive necrosis of patient 2. These findings indicated that mbIL-7-TILs could efficiently home to tumor lesions and sustainably enhance antitumor immunity in situ, suggesting potent therapeutics to treat advanced OC.
Guo et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: